Right ventricular obstructive hypertrophic
cardiomyopathy in primary Myo-Adenylate
Deaminase Deficiency by DE GREGORIO, C. et al.
46
Acta Myologica • 2011; XXX: p. 46-48
MyoAdenylate  Deaminase  Deficiency  (MADD)  is  a  relatively 
common metabolic disorder of the skeletal muscle. Patients with 
MADD usually show an impaired bioenergetic production and a 
clinical spectrum with either exercise-induced muscle pain, fa-
tigue and/or rhabdomyolysis.
Left ventricular hypertrophy as well as other types of cardiac in-
volvement have been reported in patients with primary MADD.
We describe herein a case of a 61-year-old woman with biochemi-
cal and genetic evidence of Myo-Adenylate Deaminase deficiency, 
in whom we found a right ventricular hypertrophic cardiomy-
opathy leading to severe outflow tract dynamic obstruction. 
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ventricular hypertrabeculation, right ventricular hypertrophic car-
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Introduction
Myo-Adenylate  Deaminase  deficiency  (MADD)  is 
a relatively common metabolic disorder of the skeletal 
muscle firstly described in 1978 (1). The enzyme is one 
of the most active in the purine nucleotide cycle, playing 
the adenosine-5-monophosphate deamination and main-
taining the high adenosine-5-triphosphate/-diphosphate/-
monophosphate ratio necessary for the bionergetic me-
tabolism of the working muscle. 
Because of the variety of genetic expression of such 
mutant alleles, the syndrome ranges from asymptomat-
ic carriers to patients showing exercise-induced muscle 
pain, fatigue, intolerance to exercise, and/or rhabdomy-
olysis (rare) (2-6). 
A morphofunctional involvement of the left ventri-
cle (LV, left ventricular), chiefly consisting of myocar-
dial hypertrophy or hypertrabeculation (HT), has been 
described in some MADD patients (7, 8). 
We report a peculiar case of right ventricular (RV, 
right ventricle) hypertrophic cardiomyopathy leading to 
severe dynamic obstruction across the outflow tract.
Case report
A 61-year-old woman presented with a long-lasting 
history of diffuse myalgias, cramps at lower limbs, fa-
tigue and exercise intolerance. Her family history was 
unremarkable for neuromuscular disorders, heart diseases 
and conventional cardiovascular risk factors.
Neurological  examination  showed  mild  proximal 
muscle weakness, more pronounced at lower limbs. Lab-
oratory measurements showed mild CK elevation (397 
U/l; reference range, < 200 U/l). Electromyography was 
unremarkable,  whereas  muscle  biopsy  revealed  unspe-
cific morphological alterations, but totally absent histo-
chemical staining for MAD. Biochemical study on mus-
cle homogenate also evidenced a virtual absence of MAD 
activity. Analysis of adenosin-monophosphate-deaminase 
1 (AMPD-1) gene identified the common mutation C34T 
in an homozygous state, which confirmed the diagnosis 
of MADD.
As  routinely  scheduled  in  our  neuromuscular  pa-
tients, she was referred to the cardiology department for 
heart evaluation. 
Physical examination revealed resting heart rate of 75 
bpm and sitting blood pressure of 135/80 mm Hg. Intense 
systolic murmur (Levine grade 4) was electively heard on 
the pulmonary valve. 
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Resting  ECG  (Fig.  1)  revealed  sinus  rhythm  (75 
bpm), normal atrio-ventricular conduction time (180 ms), 
right bundle branch block (QRS duration < 120 ms), high 
S-wave voltage in leads V4-5 and negative T-waves in 
leads V1-5, with no serious arrhythmias at 24-hour ECG 
monitoring.
Transthoracic  echocardiography  showed  normal 
LV morphofunctional indices at rest, but concentric RV 
hypertrophy (free-wall diastolic thickness 8 mm). Global 
systolic function was preserved (ejection fraction ≥ 0.60) 
in both ventricles, with normal fractional shortening. Tri-
cuspid and mitral annulus plane systolic excursion were 
20 and 17 mm, respectively. Possible endomyocardial HT 
was seen in the RV outflow tract (Fig. 2, A-B) to be as-
sociated to a muscular obstruction leading to severe dy-
namic gradient throughout the outflow tract (peak value 
60-70 mm Hg) (Fig. 2, C-D). 
The patient underwent gadolinium-enhanced cardiac 
magnetic resonance imaging (MRI), which confirmed the 
RV free wall hypertrophy, but also demonstrated a giant 
moderator band, both leading to outflow tract occlusion 
(Fig. 2, E-F). No signs of RV dysplasia or delay enhance-
ment were recognized. 
Discussion
This report shows a novel RV disease in a MADD 
patient, chiefly consisting with severe hypertrophy of the 
free wall and the moderator band. These morphofunc-
tional findings may be similar to those from patients with 
RV  arrhythmogenic  dysplasia,  but  the  lack  of  specific 
MRI findings, delay enhancement, typical premature ven-
tricular beats, epsilon potentials at ECG and myocardial 
vacuolations  allowed  us  to  exclude  that  cardiomyopa-
thy (9, 10).
Interestingly, prominent trabeculations into the RV, 
like in our patient, are quite hard to be interpreted prop-
erly. In fact, due to its irregular structure, the diagnosis of 
RV-HT is challenging. The criteria proposed by Jenni et 
al. (11) and Stollberger et al. (12) for LV-HT barely ap-
ply to the RV. As recently emphasized by Limongelli et 
al. (13) multiple or exaggerated trabeculations can be a 
normal variant of the RV, and there is no chance for both 
echocardiography and cardiac MRI to discriminate be-
tween the two conditions. Nevertheless, RV-HT has been 
described in neonatal decompensated hearts (14, 15).
The  severe  RV  dynamic  obstruction  is  of  clinical 
concern because of: a) its influence on patient’s symp-
toms (fatigue, breathlessness), b) few chances of reducing 
the gradient noninvasively.
In conclusion, although genetic relationships between 
neurological and cardiological features are not well de-
fined, this report confirms the need for a comprehensive 
investigation of the heart in MADD patients, bearing in 
mind that the above described symptoms could be the 
consequence of undervalued heart failure.
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Figure 2. Ultrasound imaging of the right ventricular hypertrophy and hypertrabeculation (panels A and B) causing 
severe dynamic obstruction through the outflow tract (panels C and D). Panels E and F show cardiac magnetic reso-
nance imaging  in diastole and systole, respectively. Note the hypertrophy of the basal RV free wall and of the moderator 
band (arrows), both leading to a virtual systolic chamber with outflow tract obliteration. LA, left atrium; LV, left ventricle; 
RA, right atrium, RV, right ventricle.